A Study of HS-20124 in Patients with Advanced Solid Tumors

NCT06763159 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Cancer

Interventions

DRUG: HS-20124 (Phase Ia：Dose escalation )
DRUG: HS-20124 (Phase Ib: Dose expansion)

Sponsor

Hansoh BioMedical R&D Company